Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) is a commercial-stage rare disease company whose news flow centers on its therapies for serious, low-prevalence conditions and the corporate developments that support these programs. The company regularly issues updates describing progress with its approved products, clinical pipeline, regulatory interactions, and financial performance.
A major theme in Zevra’s news is the commercialization and clinical evidence for MIPLYFFA (arimoclomol), its approved therapy for Niemann-Pick disease type C (NPC). Press releases highlight pivotal and long-term data, presentations at scientific and patient-focused meetings, and steps to broaden access, such as a distribution agreement with Uniphar to enable reimbursed named patient supply for NPC patients in select territories outside Europe. These items provide insight into how Zevra is working to expand the reach of its NPC treatment.
News coverage also includes updates on OLPRUVA (sodium phenylbutyrate), Zevra’s approved treatment for certain urea cycle disorders, and on celiprolol, its investigational candidate for vascular Ehlers-Danlos syndrome. The company reports on clinical trial enrollment milestones, publication of new analyses, and recognition of its scientific work at conferences, giving investors and clinicians visibility into the evolution of its rare disease portfolio.
In addition, Zevra issues quarterly financial results and corporate updates, detailing revenue contributions from its commercial products, operating expenses, and capital resources. Governance and organizational news, such as board appointments, executive transitions, and equity inducement grants under its employment inducement award plan, are disclosed through press releases and Form 8-K filings. For anyone tracking ZVRA, this news stream offers a consolidated view of the company’s therapeutic progress, regulatory status, and corporate trajectory in the rare disease space.
Zevra Therapeutics (NasdaqGS: ZVRA) has filed its definitive proxy statement with the SEC for the 2023 Annual Meeting of Stockholders set for April 25, 2023. The Company urges shareholders to vote 'FOR' the re-election of directors Richard W. Pascoe, David S. Tierney, M.D., and Christopher A. Posner using the WHITE proxy card. Zevra emphasizes that its current board has the right leadership for growth and value creation. The Company boasts a strong financial foundation with $102.9 million in cash as of December 31, 2022, and anticipates continued revenue from AZSTARYS royalties and its arimoclomol Early Access Program. The Board opposes nominees proposed by shareholder Daniel Mangless, citing risks to growth.
Zevra Therapeutics (ZVRA) announced its financial results for Q4 and FY 2022, revealing a net revenue of $2.3 million for Q4, down from $2.6 million in 2021. The company reported a net loss of $9 million, primarily due to R&D expenses of $6.4 million. For FY 2022, net revenue was $10.5 million, significantly down from $28.7 million in 2021, attributed to a lack of one-time regulatory milestone payments. Zevra holds $102.9 million in cash, extending its runway into 2026. The company is focused on advancing its arimoclomol NDA resubmission and KP1077 Phase 2 trial, with key data expected in Q3 and year-end 2023.
Zevra Therapeutics, previously known as KemPharm, announced that CEO Richard W. Pascoe will participate in a fireside chat at the 35th Annual Roth Conference on March 13, 2023, at 2:00 p.m. PT. During this session, Pascoe will outline the company’s innovative clinical, regulatory, and commercialization strategies aimed at advancing therapies for rare diseases. The chat will be accessible in-person and online, with a replay available for 90 days. Investors can also schedule one-on-one meetings with Zevra management from March 12-14. More details are available on Zevra's corporate website.
Zevra Therapeutics (Nasdaq: ZVRA), previously KemPharm, has begun trading under its new ticker symbol on the Nasdaq Global Select Market as of March 1, 2023. The company's rebranding reflects its commitment to the rare disease community. Zevra is developing arimoclomol, an investigational treatment for Niemann-Pick type C disease, which currently has no approved U.S. therapies. The FDA has granted arimoclomol orphan drug designation, Fast Track designation, and rare pediatric disease designation. Zevra is also progressing KP1077, aimed at treating idiopathic hypersomnia, now in a Phase 2 trial. Key milestones for 2023 include a planned resubmission of the NDA for arimoclomol.